A Pilot Study to Evaluate the Feasibility and Safety of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV-HIV CAR) T Cells in People Living With HIV.

This document provides information about a pilot study that aims to evaluate the feasibility and safety of using cytomegalovirus-specific, anti-HIV chimeric antigen receptor (CMV-HIV CAR) T cells as a potential immunotherapy for people living with HIV. The study focuses on the use of CAR T cells engineered to target HIV-infected cells, with the goal of eliminating these cells. The researchers propose using autologous CMV-specific T cells, which can be stimulated by endogenous CMV, to address the issue of low persistence of CAR T cells. The study is in its early stages and aims to assess the presence and effectiveness of CMV/HIV-CAR T cells in healthy individuals living with HIV. [Extracted from the article]